458 related articles for article (PubMed ID: 26774923)
1. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
2. Homology modeling and explicit membrane molecular dynamics simulation to delineate the mode of binding of thiazolidinediones into FFAR1 and the mechanism of receptor activation.
Helal MA; Darwish KM; Hammad MA
Bioorg Med Chem Lett; 2014 Nov; 24(22):5330-6. PubMed ID: 25441945
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
6. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
7. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
9. PPARγ signaling and emerging opportunities for improved therapeutics.
Wang S; Dougherty EJ; Danner RL
Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
[TBL] [Abstract][Full Text] [Related]
10. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
11. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
Banerjee PS; Samanta S
Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and molecular docking investigation of benzhydrol- and indole-based dual PPAR-γ/FFAR1 agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Khafagy ES; Helal MA
Bioorg Med Chem Lett; 2018 May; 28(9):1595-1602. PubMed ID: 29615345
[TBL] [Abstract][Full Text] [Related]
14. Rational design and synthesis of some PPAR-γ agonists: Substituted benzylideneamino-benzylidene-thiazolidine-2,4-diones.
Chhajed SS; Chaskar S; Kshirsagar SK; Haldar GM; Kar Mahapatra D
Comput Biol Chem; 2017 Apr; 67():260-265. PubMed ID: 28193552
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers.
Huiying Z; Guangying C; Shiyang Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):981-989. PubMed ID: 31072232
[TBL] [Abstract][Full Text] [Related]
16. In silico design, chemical synthesis and toxicological evaluation of 1,3-thiazolidine-2,4-dione derivatives as PPARγ agonists.
Alemán-González-Duhart D; Tamay-Cach F; Correa-Basurto J; Padilla-Martínez II; Álvarez-Almazán S; Mendieta-Wejebe JE
Regul Toxicol Pharmacol; 2017 Jun; 86():25-32. PubMed ID: 28202347
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
18. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
Arlt W; Neogi P; Gross C; Miller WL
J Mol Endocrinol; 2004 Apr; 32(2):425-36. PubMed ID: 15072549
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Nazreen S; Alam MS; Hamid H; Shahar Yar M; Dhulap A; Alam P; Pasha MA; Bano S; Alam MM; Haider S; Kharbanda C; Ali Y; Pillai K
Arch Pharm (Weinheim); 2015 Jun; 348(6):421-32. PubMed ID: 25900064
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
